Abstract

ObjectivesEfficacy and safety of erenumab, a human anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody, were evaluated in patients with episodic migraine (EM) in a phase 3 trial (NCT02483585).MethodsFive-hundred and seventy...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call